We think that there are some constructive conversations. We've talked about the fact that there's three legs to our stool on reimbursement, being the cost of the drug and the margin associated with that, our clinical per diems. and then the nursing rate. And we're always looking for getting balance within that as to the contribution on that. We don't break it out, we don't provide that level of detail, but there's always that focus for us as an organization. And I think in the conversations that we have with our payer partners through that, I think they have a recognition of that value and how we can help bend the trend of the total cost of care in that equation.

Jul 31, 2024 / receipt, needs a key / John, CEO | earnings call 2024-07-31 | transcript 319d664e-3c79-4164-a73d-b3acb46019df | chars 38765-39436 | segment 39